Domov › Srpastocelična anemija › Illinois
Klinične študije za Srpastocelična anemija v Illinois
19 študij za Srpastocelična anemija išče udeležence na lokacijah v Illinois.
Mesta v Illinois
Uradno besedilo študije (angleško)
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- University of Illinois at Chicago College of Medicine, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT04055818A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Uni of Illinois Hospital and HSC, Chicago
Vključevanje udeležencevFaza 3
Starost 12–100 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Illinois Hospital and Health Sciences System, Chicago
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Univer Of Illinois at Chicago, Chicago
Vključevanje udeležencevFaza 3
Starost 2 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Childrens Hospital of Chicago, Chicago
- Univer Of Illinois at Chicago, Chicago
Vključevanje udeležencevFaza 3
Starost 12 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06612268Tocilizumab for Acute Chest Syndrome
- University of Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 12 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT05640271A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0034, Chicago
Vključevanje udeležencevFaza 1/2Vabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- University of Illinois at Chicago Clinical Research Center, Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
Vključevanje udeležencevFaza 2/3
Starost 12 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Rush University Medical Center, Chicago
- Bleeding and Clotting Disorders Institute, Peoria
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Illinois at Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 12 in več · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT06699849The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago
Vključevanje udeležencevFaza 3
Starost 10–65 · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT06975865Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- University of Illinois at Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 16–60 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT03121001Sickle Cell Clinical Research and Intervention Program
- Children's Hospital of Illinois at OSF-Saint Francis Medical Center, Peoria
Vključevanje udeležencevOpazovalna študija
Vse starosti · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT02098863Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Comer Children's Hospital (MRD-HCT), Chicago
Vključevanje udeležencevOpazovalna študija
Starost 3–20 · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT06941389Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- University of Illinois Chicago, Sickle Cell Center, Chicago
Vključevanje udeležencevFaza 2
Starost 18–60 · Vsi spoli · Posodobljeno 19. maj 2026 · NCT07175051Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- University of Illinois at Chicago, Chicago
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 23. mar. 2026 · NCT06919224Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Vključevanje udeležencevFaza 2
Starost 2–25 · Vsi spoli · Posodobljeno 10. mar. 2026 · NCT03587272Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
Vključevanje udeležencev
Starost 16–30 · Vsi spoli · Posodobljeno 7. jan. 2026 · NCT06374238Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Illinois, Chicago
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 22. jun. 2025 · NCT06385886Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.